Land: Kanada
Sprache: Englisch
Quelle: Health Canada
TESTOSTERONE CYPIONATE
PFIZER CANADA ULC
G03BA03
TESTOSTERONE
100MG
SOLUTION
TESTOSTERONE CYPIONATE 100MG
INTRAMUSCULAR
10ML
Schedule G (CDSA IV)
ANDROGENS
Active ingredient group (AIG) number: 0106401001; AHFS:
APPROVED
2001-06-04
_ _ _DEPO-TESTOSTERONE Product Monograph _ _ _ _Page 1 of 20_ PRODUCT MONOGRAPH DEPO-TESTOSTERONE testosterone cypionate injection 100 mg/mL sterile solution USP Androgens Pfizer Canada Inc. 17, 300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Revision: July 12, 2018 Submission Control No: 217239 © Pfizer Canada Inc., 2018 _ _ _DEPO-TESTOSTERONE Product Monograph _ _Page 2 of 20 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 DOSAGE FORMS, COMPOSITION AND PACKAGING ...............................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................8 DRUG INTERACTIONS ....................................................................................................9 DOSAGE AND ADMINISTRATION ..............................................................................10 OVERDOSAGE ................................................................................................................11 ACTION AND CLINICAL PHARMACOLOGY ............................................................12 STORAGE AND STABILITY ..........................................................................................13 SPECIAL HANDLING INSTRUCTIONS .......................................................................14 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................14 PART II: SCIENTIFIC INFORMATION ...............................................................................15 PHARMACEUTICAL INFO Lesen Sie das vollständige Dokument